文献速递淋巴瘤

Musashi-2在侵袭性套细胞淋巴瘤中的致瘤作用

Tumorigenic role of Musashi-2 in aggressive mantle cell lymphoma.
PubMed 文献 · Leukemia · 2022-12-12

研究探讨SOX11阳性套细胞淋巴瘤中干细胞相关基因的富集,发现MSI2是SOX11直接上调的关键基因,其高表达与总生存期差独立相关;MSI2敲低可降低克隆生长、肿瘤细胞存活和化疗耐药,并减少小鼠异种移植模型中的致瘤性植入。

要点

  • SOX11阳性套细胞淋巴瘤富集白血病和造血干细胞基因特征,MSI2为显著上调的干细胞相关基因之一。
  • SOX11直接结合MSI2启动子并上调其表达,MSI2内含子增强子在SOX11阳性套细胞淋巴瘤细胞系和原发病例中强激活。
  • MSI2上调与其他套细胞淋巴瘤高危特征无关,独立与总生存期差显著相关。

核心结论

  • MSI2可能在维持干性和肿瘤细胞存活中起关键作用,是套细胞淋巴瘤治疗干预的潜在新靶点。

研究设计与样本

  • 研究比较SOX11阳性与SOX11阴性套细胞淋巴瘤原发病例的干细胞基因特征,并在体外细胞系和异种移植小鼠模型中验证MSI2功能。

主要发现

  • SOX11阳性较SOX11阴性套细胞淋巴瘤原发病例富集白血病和造血干细胞基因特征。
  • MSI2是SOX11阳性套细胞淋巴瘤中显著上调的干细胞相关基因之一。
  • SOX11在体外直接结合MSI2启动子上调其表达。
  • MSI2内含子增强子在SOX11阳性套细胞淋巴瘤细胞系和原发病例中强激活。
  • MSI2上调与其他套细胞淋巴瘤高危特征无关,独立与总生存期差显著相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

SOX11 overexpression has been associated with aggressive behavior of mantle cell lymphomas (MCL). SOX11 is overexpressed in embryonic and cancer stem cells (CSC) of some tumors. Although CSC have been isolated from primary MCL, their relationship to SOX11 expression and contribution to MCL pathogenesis and clinical evolution remain unknown. Here, we observed enrichment in leukemic and hematopoietic stem cells gene signatures in SOX11+ compared to SOX11- MCL primary cases. Musashi-2 (MSI2) emerged as one of the most significant upregulated stem cell-related genes in SOX11+ MCLs. SOX11 is directly bound to the MSI2 promoter upregulating its expression in vitro. MSI2 intronic enhancers were strongly activated in SOX11+ MCL cell lines and primary cases. MSI2 upregulation was significantly associated with poor overall survival independently of other high-risk features of MCL. MSI2 knockdown decreased the expression of genes related to apoptosis and stem cell features and significantly reduced clonogenic growth, tumor cell survival and chemoresistance in MCL cells. MSI2-knockdown cells had reduced tumorigenic engraftment into mice bone marrow and spleen compared to control cells in xenotransplanted mouse models. Our results suggest that MSI2 might play a key role in sustaining stemness and tumor cell survival, representing a possible novel target for therapeutic interventions in MCL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Sureda-Gómez M, Balsas P, Rodríguez ML, et al. Tumorigenic role of Musashi-2 in aggressive mantle cell lymphoma. Leukemia. 2022. PMID: 36509891. doi:10.1038/s41375-022-01776-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。